Premium
Use of repaglinide on a pregnant woman during embryogenesis
Author(s) -
MollarPuchades M. A.,
MartinCortes A.,
PerezCalvo A.,
DiazGarcia C.
Publication year - 2007
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/j.1463-1326.2006.00629.x
Subject(s) - repaglinide , pregnancy , medicine , gestational diabetes , obstetrics , insulin , gestation , metformin , endocrinology , biology , genetics
In the past few years, oral antihyperglycaemic agents have been considered as an alternative to insulin therapy in the treatment of gestational diabetes. There is still little information available on the safety of these drugs during pregnancy, but there have been several studies published regarding their use. Here we report on the case of a woman who took repaglinide up to the seventh week of pregnancy. Delivery occured with no complications and the newborn showed no malformations. Further studies are required to confirm the safety of repaglinide during pregnancy.